← Leaderboards
Buddhadev Layek
North Dakota State University
$884,621
Attributed
$884,621
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $227.9K · FY2022–25$250K$187.5K$125K$62.5K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$884,621 · 1
By mechanism
P20$884,621 · 1
Top collaborators
No co-investigators on record.
Most similar at North Dakota State University
Same institution · by research overlap
- Megan Orr$580,671
Others in their field
Other Rising Stars on “Drug Kinetics”
- Kevin V Grimes · Stanford University$14,783,804
- Heinz Ernst Moser · University Of Texas Med Br Galveston$13,657,841
- Colin Osborne · University Of Texas Med Br Galveston$10,407,745
- Taleen Hanania · Psychogenics, Inc.$9,482,040
- Joseph Fraser Glickman · Hackensack University Medical Center$8,363,749
- Alexander Kolykhalov · Emory University$8,116,465
Research focus
Drug KineticsDoseDrug Delivery SystemsAcuteAffectApoptosisAutopsyAcute ToxicityBehaviorBiodistributionAntineoplastic AgentsCancer TherapyCell KillingCellsChargeChemotherapeutic AgentChemotherapyCombined Modality TherapyCytotoxicCytotoxic AgentDesmoplasticDiagnosticBiomedical EngineeringDrug Release Kinetics
Grant awards (4)
Mesenchymal Stem Cell-Based Targeted Combined Therapy for Pancreatic Ductal Adenocarcinoma$227,867
P20 · FY2025 · GM · contact PI
Mesenchymal Stem Cell-Based Targeted Combined Therapy for Pancreatic Ductal Adenocarcinoma$224,580
P20 · FY2024 · GM · contact PI
Mesenchymal Stem Cell-Based Targeted Combined Therapy for Pancreatic Ductal Adenocarcinoma$226,317
P20 · FY2023 · GM · contact PI
Mesenchymal Stem Cell-Based Targeted Combined Therapy for Pancreatic Ductal Adenocarcinoma$205,857
P20 · FY2022 · GM · contact PI